| 181 | 3 | 62 |
| 下载次数 | 被引频次 | 阅读次数 |
目的:观察活血祛湿方联合针灸对乙型肝炎肝硬化糖尿病患者肝细胞胰岛素抵抗的影响。方法:以68例乙型肝炎肝硬化糖尿病患者为研究对象,按随机数字表法分为中药组与针药组各34例。对两组患者进行控制血糖、保肝、抗病毒等基础性治疗。中药组患者在此基础上每日口服活血祛湿方,日1剂。针药组患者在中药组治疗基础上同时选取脾俞、胃脘下俞、肾俞、肝俞、三阴交、足三里、中脘、丰隆,进行针刺治疗。疗程为2个月。观察治疗前后胰岛素抵抗指数(HOMA-IR)、空腹血糖(FPG)、糖化血红蛋白(HbA1c)、餐后2 h血糖(2 hPG)、瘦素(LEP)、脂联素(ADPN)水平、体质量指数(BMI)、证候积分、FPG、HbA1c、2 hPG肠道菌群水平及临床疗效。结果:治疗后,中药组及针药组HOMA-IR、BMI、腹胀积分、肢体沉重积分、肢体浮肿积分、肌肤甲错积分、LEP水平、肠道大肠埃希菌水平均较治疗前减少,ADPN水平、双歧杆菌水平均较治疗前升高,且针药组改变程度更明显(P<0.05)。治疗后,中药组治疗总有效率76.47%,针药组97.06%,两组疗效比较,差异具有统计学意义(P<0.05)。结论:活血祛湿方联合针刺可通过保护肝细胞、提高胰岛素利用率、促进胰岛β细胞释放、降低感染程度等方式,改善肝源性糖尿病患者胰岛素抵抗,提高治疗效果。
Abstract:Objective : To observe the effect of Huoxue Qushi Formula ( 活 血 祛 湿 方 ) combined with acupuncture on insulin resistance of liver cells in patients with diabetes Caused by Hepatitis B Cirrhosis.Methods:A total of 68 patients with hepatitis B,liver cirrhosis and diabetes were included and divided into Chinese medicinals group and acupuncture and medicinals group with a random number table,34 patients in each group. Both groups were given routine treatments including treatments for blood glucose control,liver protection,and antivirus. Chinese medicinals group was given oral administration of Huoxue Qushi Formula,one dose a day. Acupuncture and medicinals group were further treated with acupuncture on Pishu(BL 20),Weiwanxiashu(EX-B 3),Shenshu(BL 23),Ganshu(BL 18),Sanyinjiao(SP 6),Zusanli(ST 36),Zhongwan(CV 12),and Fenglong(ST 40) besides the treatment in the Chinese medicinals group. The treatment lasted for 2 months. Before and after treatment,homeostasis model assessment for insulin resistance(HOMA-IR),fasting plasma glucose(FPG),glycosylated hemoglobin A1C(HbA1C),2 h postprandial blood glucose(2 h PG),leptin(LEP),adiponectin(ADPN) levels,body mass index(BMI),intestinal flora level were tested,syndromes score and efficacy were compared. Results:After treatment,HOMA-IR,BMI,abdominal distension score,limb weight score,limb edema score,scaly skin score,LEP levels,and intestinal Escherichia coli levels were reduced before treatment in Chinese medicinals group and the acupuncture and Chinese medicinal group,while levels of ADPN and Bifidobacteria increased compared with before treatment,and the changes were more obvious in the acupuncture and medicinals group(P<0.05). After treatment,the total efficacy rate was 76.47% in the Chinese medicinals group and 97.06% in the acupuncture and medicinals group. Acupuncture and medicinals group was significantly higher than Chinese medicinals group on the efficacy rate, with statistical difference( P < 0. 05). Conclusions : Huoxue Qushi Formula combined with acupuncture can improve the insulin resistance of patients with liver-derived diabetes by protecting liver cells,increase the utilization rate of insulin,promote the release of islet β-cells,reduce the degree of infection,and improve the total efficacy.
[1]李克田,沈明格,王凤荣,等.血糖水平对原发性肝癌患者18F-FDG摄取和PET/CT检查图像质量的影响研究[J].实用肝脏病杂志,2019,22(2):256-259.
[2]胡晗,田彩云,张国远,等.肝源性糖尿病发病机制的最新进展[J].临床肝胆病杂志,2021,37(2):429-432.
[3]田彩云,胡晗,张国远,等.肝源性糖尿病的诊断研究进展[J].中国全科医学,2021,24(9):1158-1164.
[4]刘鲁豫,刘爱霞,刘亚珠.门冬胰岛素50注射液联合前列地尔治疗肝源性糖尿病的血糖控制效果及对PCⅢ、LN水平的影响[J].中国药师,2020,23(12):2415-2417.
[5]林振德,江连发,陈景象,等.恩替卡韦治疗乙型肝炎肝硬化并发肝源性糖尿病(HD)患者疗效分析[J].糖尿病新世界,2020,23(7):45-46.
[6]鲁明月,李静.肝源性糖尿病的发病机制及诊疗进展[J].锦州医科大学学报,2018,39(6):92-96.
[7]刘纯,明洁,徐少勇,等.肝源性糖尿病的诊断和治疗[J].医学综述,2018,24(8):1580-1585.
[8]周仲瑛.中医内科学[M].北京:中国中医药出版社,2007:407-414.
[9]郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:29-31.
[10]冯学才.恩替卡韦治疗乙型肝炎肝硬化伴肝源性糖尿病的临床疗效研究[J].糖尿病新世界,2020,23(1):10-12.
[11]张国忠,娄金丽,汪洋,等.慢性乙型肝炎伴肝源性糖尿病和肝硬化伴肝源性糖尿病患者肝纤维化指标与胰岛素抵抗的相关性分析[J].临床和实验医学杂志,2018,17(15):1610-1612.
[12]李洪焱,唐科江.乙肝后肝硬化与糖耐量异常、胰岛素抵抗的相关性探讨[J].现代中西医结合杂志,2015,24(21):2329-2331.
[13]李波,王晓栋,陈茂林,等.肝源性糖尿病胰岛素抵抗与谷氨酸脱羧酶抗体的相关性研究现状[J].西南医科大学学报,2019,42(6):585-588.
[14]杨超.活血祛湿法治疗2型糖尿病伴胰岛素抵抗的临床研究[J].齐齐哈尔医学院学报,2016,37(6):716-717.
[15]阮东英.黄芪泡服联合中药熏洗对糖尿病下肢周围神经病变患者血糖控制及TCSS评分的影响[J].中国疗养医学,2020,29(11):1222-1223.
[16]李海燕,徐芬,马朝阳.基于“标本配穴”理论针灸干预疗法对单纯性肥胖患者血脂水平及胰岛素抵抗的影响[J].中华中医药学刊,2019,37(1):49-52.
[17]虞莉青,曹莲瑛,谢菁,等.电针治疗胰岛素抵抗型多囊卵巢综合征疗效与作用机制研究[J].中国针灸,2020,40(4):379-383.
[18]毛黎明,朱斌,富佳杰,等.糖尿病肾病Ⅳ期患者血清ADPN、VEGF的水平及其与尿蛋白、eGFR的相关性分析[J].中国中西医结合肾病杂志,2018,19(12):1064-1067.
[19] LE CHATELIER E,NIELSEN T,QIN J J,et al. Richness of human gut microbiome correlates with metabolic markers[J]. Nature,2013,500(7464):541-546.
基本信息:
DOI:10.16295/j.cnki.0257-358x.2022.09.012
中图分类号:R259
引用信息:
[1]杨晶,卞蓉.活血祛湿方联合针刺对乙型肝炎肝硬化糖尿病患者肝细胞胰岛素抵抗的影响[J],2022,41(09):984-989.DOI:10.16295/j.cnki.0257-358x.2022.09.012.
基金信息:
辽宁省科学计划项目(编号:2019-ZD-0436)